Telomir Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 6, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Reporting period: Quarter ended September 30, 2026, filed November 6, 2026.
  • Shares outstanding: 73,675,706 shares of common stock issued and outstanding as of November 5, 2026, according to the filing.
  • Exchange listing: Common stock, no par value, trades on The Nasdaq Capital Market under the symbol TELO (NASDAQ:TELO).
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Shell company status: The registrant indicated it is not a shell company, as defined in Rule 12b-2 of the Exchange Act.
  • Pending litigation noted: The filing identifies "the pending Chapman Litigation" as a risk factor affecting the company's forward-looking statements.

Telomir Pharmaceuticals: Company Profile and Filing Details

Telomir Pharmaceuticals, Inc. is a Florida-incorporated pharmaceutical company headquartered at 100 SE 2nd St, Suite 2000 #1009, Miami, Florida 33131, with Commission File Number 001-41952 and IRS Employer Identification Number 87-2606031. The company's common stock carries no par value and is registered on The Nasdaq Capital Market under ticker symbol TELO, as stated on the cover page of this quarterly report.

According to the filing, the company confirmed it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically. As an emerging growth company, the registrant has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

The filing's cautionary note identifies several specific risk areas that the company disclosed as potentially affecting future results. These include the ability to obtain regulatory approval for product candidates, plans for a Phase 1/2 clinical trial, maintenance of compliance with Nasdaq continued listing requirements, the concentration of ownership among Bayshore Trust and the Chief Executive Officer, and the effect of "the pending Chapman Litigation." The company also flagged risks related to a Private Placement and related resale registration as factors that could cause dilution and potential market impact. All forward-looking statements in the filing are the company's own and are subject to its cautionary language.

What Was Disclosed

Telomir Pharmaceuticals, Inc. submitted its Form 10-Q for the quarter ended September 30, 2026, reporting 73,675,706 shares outstanding as of November 5, 2026. The filing identified the company as a smaller reporting company and emerging growth company listed on NASDAQ:TELO.